NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) issued its earnings results on Monday, November, 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History.

Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals.

11 brokers have issued 1-year target prices for Deciphera Pharmaceuticals' stock. Their forecasts range from $29.00 to $84.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $61.17 in the next year. This suggests that the stock has a possible downside of 8.1%. View Analyst Price Targets for Deciphera Pharmaceuticals.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.

Press coverage about DCPH stock has been trending somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,500,000 shares, an increase of 7.8% from the December 15th total of 2,320,000 shares. Based on an average daily trading volume, of 544,200 shares, the short-interest ratio is currently 4.6 days. Currently, 8.0% of the company's stock are short sold. View Deciphera Pharmaceuticals' Current Options Chain.

Some companies that are related to Deciphera Pharmaceuticals include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP).

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $66.57.

Deciphera Pharmaceuticals has a market capitalization of $3.40 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals.

The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]